AllDocs -> cancers

www.datamonitor.com/healthcare Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads A Datamonitor Report Published: Jul-05 Product Code: DMHC2102 Use this Report to Understand the limitations of current therapy available to glioma patients Providing you with: • Overview of disease including epidemiology, biology of glioma and prognostic variables • Current treatment options and clinical controversies, including comments from opinion leaders • Key recommendations in the areas of greatest unmet need in glioblastoma patients • Profiles of agents in late stage development, including opinions from glioma specialists Page 2 Stakeholder Opinions: Primary Brain Cancer – Temozolomide Turns Heads DMHC2102 The incidence of glioblastoma is increasing. ...

Massachusetts Department Of Public Health Center for Environmental Health, Community Assessment Program Evaluation of Brain and Central Nervous System Cancer Incidence in Arlington, Massachusetts 1982-2001 October 2005 Page 2 i I. INTRODUCTION 1 II. METHODS FOR ANALYZING CANCER INCIDENCE. 2 A. Case Identification/Definition 2 B. Calculation of Standardized Incidence Ratios (SIRs) 3 C. Interpretation of a Standardized Incidence Ratio (SIR) 4 D. Calculation of the 95% Confidence Interval.. 5 E. Evaluation of Cancer Risk Factor Information. 6 F. Determination of Geographic Distribution of Cancer Cases. 6 G. Cancer Incidence in the Reeds Brook Landfill Neighborhood. 7 III. FORMER REEDS BROOK LANDFILL 7 IV. RESULTS OF CANCER INCIDENCE ANALYSIS ...

Web Sites Blood disorders: http://www.haemophilia.org.uk/factors.html Brain : http://www.brainplace.com/bp/default.asp Cancer : http://webmd.lycos.com/content/asset/adam_disease_neoplasm CDC Topics: http://www.cdc.gov/health/default.htm#M Communicable Disease Index: http://www.metrokc.gov/health/prevcont/ Conditions: http://www.rarediseases.org/lof/lof.html Conditions: http://www.aarda.org/directry.html Conditions and Summaries: http://www.bestdoctors.com/en/conditions/index.htm Drugs: http://www.nlm.nih.gov/medlineplus/druginformation.html First Aid: http://www.healthlinkusa.com/getpage.asp?http://www.survival-center.com/firstaid/burns.htm Food Allergies: http://www.foodallergy.org/ Health Topics: http://www.nlm.nih.gov/medlineplus/healthtopics.html ...

Primary brain and other central nervous system (CNS) cancers made up 1.4 percent of the incident (newly diagnosed) cancers reported to the Ohio Cancer Incidence Surveillance System (OCISS) for the years 1997 through 2001 (Table 1). Primary tu- mors, or those tumors that originate in the brain or CNS, serve as the focus of this report. The average annual age-adjusted brain and other CNS cancer incidence rate during this time period was 6.8 cases per 100,000 residents (an average of 784 cases per year). Average annual numbers and rates represent the number of cases diagnosed per year on average, not the total number of cases diagnosed during the five-year time period. The average annual age-adjusted U.S. (SEER 1 ) incidence rate for 1997-2001 was 6.4 cases per 100,000 residents, which is about 6 percent less than the rate for Ohio. Completeness of reporting of brain and other CNS cancer ...

EFORE the advent of GKS, fractionated radiotherapy and resection were the mainstays of treatment for brain metastases. Now, GKS offers effective tumor control and a relatively long survival period for patients compared with the natural history of the disease. Moreover, it does so while causing minimal morbidity and essentially no deaths. Radiosurgery can be used to treat multiple metas- tases during the same procedure and permits treatment of deep deposits considered surgically inaccessible. 3,4,8–11,16–18, 20,23,24 To date, however, the influence of factors such as WBRT, tumor histology, tumor volume, patient age, preop- erative KPS score, control of the primary disease, and the presence of extracranial metastatic disease on the outcome of lung carcinoma brain metastases after GKS remain the subject of debate. 9,12,15,19,22,25 The aim of this study was to ...

HEMOTHERAPY and/or WBRT have been the gold standards for metastatic brain tumors from SCLC because SCLCs characteristically spread rapidly and result in numerous microscopic brain metasta- ses. 1,9,10,12 Few reports on radiosurgery for metastatic SCLC-induced brain tumors are available. In this retro- spective study, we reviewed the results of GKS alone for the treatment of brain metastases from SCLC compared with the results from NSCLC according to the same treat- ment protocol at a single institute. Clinical Material and Methods Patient Population Three hundred twenty-four patients with metastatic brain tumors from lung cancer were treated at the Chiba Cardiovascular Center between January 1998 and De- cember 2001. Data obtained in patients meeting the fol- lowing five criteria were evaluated retrospectively: 1) no prior brain tumor treatment; ...

H E in vivo t ra n s fer and ex p ression of fo reign ge n e s into malignant brain tumor cells rep resents a new t h e rapeutic ap p ro a ch for these incurable neoplasms. P revious attempts at gene tra n s fer into malignant bra i n t u m o rs have focused on the use of rep l i c at i o n - d e fi c i e n t re t rov i ruses in animal models, 3 , 6 , 8 , 1 2 , 1 4 , 1 6 as well as in an o n going clinical tri a l . 1 3 R e t rov i ruses have the adva n t age of s e l e c t ive integration into rep l i c ating cells, but their use is limited by low titer of the ve c t o r- p roducer cells, va ri abl e ex p ression of the ge n e, and the possibility of insert i o n a l mu t agenesis. Herpes simplex ve c t o rs have also been used for gene tra n s fer into the central nervous system (CNS), 1 , 7 but their poor transduction effi c i e n cy and potential neuro- ...

RIMARY lung cancer is the leading cause of death from cancer in both women and men in the United States. It is estimated that there were 170,000 new cases of lung cancer in this country in 1994, resulting in 153,000 deaths. 3 The incidence of brain metastases from lung cancer is reported to be approximately 34% in an autopsy series. 52 Clinical studies show that between 20% 33 and 24% 63 of patients with nonsmall-cell lung can- cer (NSCLC) are diagnosed as having brain metastases at some time during the course of their disease. As approxi- mately 80% of patients with lung cancer have NSCLC, 38 these percentages translate into 30,000 patients who will develop brain metastases from NSCLC each year. Only approximately 25% of these patients, however, will be eligible for surgical resection of their metastatic ...

BENIGN BRAIN TUMOR CANCER REGISTRIES AMENDMENT ACT: Improving the Quality of Brain Tumor Data Background Each year, approximately 35,000 individuals in the United States are diagnosed with primary brain tumors. About half of those tumors are “benign.” However, it is difficult to differentiate between benign and malignant tumors on the basis of their microscopic appearance; some benign tumors have a propensity to become malignant over time; and some benign brain tumors recur repeatedly. Benign brain tumors may be no more responsive to treatment than malignant tumors, and both benign and malignant brain tumors present daunting treatment challenges because of their location. Improvements in our understanding of brain tumors and advances in the treatment of brain tumors depend on the collection of accurate data about brain tumors. Both the Brain Tumor Working Group of the National ...

U . S . GOVERNMENT PRINTING OFFICE WASHINGTON : For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 76–311PS 2002 RAISING HEALTH AWARENESS THROUGH EXAM- INING BENIGN BRAIN TUMOR CANCER , ALPHA ONE, AND BREAST IMPLANT ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED SEVENTH CONGRESS FIRST SESSION NOVEMBER 15, 2001 Serial No. 107–75 Printed for the use of the Committee on Energy and Commerce ( Available via the World Wide Web: http://www.access.gpo.gov/congress/house VerDate 11-MAY-2000 09:57 Jan 17, 2002 ...

Cancer in Northern Ireland 1993 - 2001: A Comprehensive Report 115 20: Cancer of the Brain (C71) Incidence In 2001, malignant primary cancer of the brain was the fifteenth most common cancer in males and twentieth commonest in females. On average, 60 males and 45 females were diagnosed as having cancer of the brain each year i.e. approximately 1% of all cancers registered. Age The median age at diagnosis was 56 years for males and 57 years for females. Given the levels of disease in 2001, the risk of getting cancer of the brain before the age of 75 years was 1 in 151 for males and 1 in 210 for females (Table 20a). Examination of the age-specific incidence rates show that males twenty years and older had consistently higher levels of this cancer than females (Figure 20a). Prevalence In Northern Ireland on 31st December 2001, there were 121 males and 117 females alive who ...

All-Ireland cancer statistics 1994-96 90 Brain 21. MALIGNANT CANCER OF THE BRAIN (summary) ICD-O.2 C71 ICD-10 C71 ICD-9 191 Figures presented are for primary, malignant tumours. Cancer of the meninges (ICD-10 C70) or of the central nervous system (C72) other than the brain itself are excluded, except where comparison is made with EU figures. Key facts • Average of 315 new cases per year, 1994-96: 148 in females, 200 in males. • Average of 297 deaths per year: 130 in females, 167 in males. • Age-standardised incidence and mortality rates about 50% higher in males than females. • 11th most common site for cancer incidence in males, 15th in females. • 8th most common cause of cancer deaths in females, 9th in males. • Median age at diagnosis 57 years for females and 55 years for males (lower than for cancers as a whole). ...

1 Brain Cancer Microarray Data Gene Co-expression Network Analysis R Tutorial Steve Horvath, Bin Zhang, Jun Dong, Andy Yip, Ai Li Correspondence: shorvath@mednet.ucla.edu , http://www.ph.ucla.edu/biostat/people/horvath.htm This R tutorial describes how to carry out a gene co-expression network analysis with the R software. We show how to construct unweighted networks using hard thresholding and how to construct weighted networks using soft thresholding. To cite this tutorial or the statistical methods please use 1. Zhang B, Horvath S (2005) A General Framework for Weighted Gene Co-Expression Network Analysis. Statistical Applications in Genetics and Molecular Biology. In Press. Technical Report and software code at: www.genetics.ucla.edu/labs/horvath/CoexpressionNetwork . For the generalized topological overlap matrix as applied to unweighted ...